68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Completed · Not applicable

Conditions studied: Neuroendocrine Carcinoma

In brief

To evaluate the concordance and discordance between results of 68Ga-DOTATATE PET-CT scan and OctreoScan ® which is considered standard of care diagnostic test for neuroendocrine cancers and other imaging modalities like CT scan/MRI as gold standard.

Key facts

Study ID
NCT01879657
Run by
Radio Isotope Therapy of America
People needed
169
Starts
2013-03-01
Expected to finish
2017-12-05
Last updated by the study team
2025-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.